6:24 PM
 | 
Dec 20, 2013
 |  BC Extra  |  Company News

BioCryst submits peramivir NDA

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) submitted an NDA to FDA for peramivir to treat acute uncomplicated influenza in adults. The IV...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >